Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
Tinevimbo Shiri
(1)
,
Angela Loyse
(2)
,
Lawrence Mwenge
(3)
,
Tao Chen
(1)
,
Shabir Lakhi
(4)
,
Duncan Chanda
(5, 6)
,
Peter Mwaba
(7)
,
Síle Molloy
(2)
,
Robert S Heyderman
(8, 9)
,
Cecilia Kanyama
(10)
,
Mina Hosseinipour
(10, 11)
,
Charles Kouanfack
(12, 13)
,
Elvis Temfack
(14, 15, 16)
,
Sayoki G Mfinanga
(17, 1)
,
Sokoine Kivuyo
(17)
,
Adrienne Chan
(18, 19)
,
Joseph Jarvis
(20, 21)
,
Olivier Lortholary
(22, 15, 16, 23)
,
Shabbar Jaffar
(1)
,
Louis Niessen
(1, 24)
,
Thomas Harrison
(2)
1
LSTM -
Liverpool School of Tropical Medicine
2 St George's, University of London
3 Zambart Health Economics Unit Lusaka
4 University Teaching Hospital (UTH), Lusaka,
5 UTH - University Teaching Hospital [Lusaka]
6 Institute for Medical Research and Training, University of Teaching Lusaka
7 Department of Internal Medicine and Directorate of Research and Post-graduate Studies, Lusaka Apex Medical University, Zambia
8 University of Malawi
9 UCL - University College of London [London]
10 UNC Project - University of North Carolina Project-Malawi
11 UNC - University of North Carolina [Chapel Hill]
12 Hôpital Central de Yaoundé [Yaoundé]
13 Université de Dschang
14 Hôpital Général de Douala
15 Mycologie moléculaire - Molecular Mycology
16 CNRMA - Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire
17 NIMR - National Institute for Medical Research - Muhimbili Research Centre
18 Zomba Central Hospital Malawi
19 University of Toronto
20 LSHTM - London School of Hygiene and Tropical Medicine
21 Bostwana Harvard AIDS Institute Partneship Gaborone
22 Centre d'infectiologie Necker-Pasteur [CHU Necker]
23 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
24 Johns Hopkins Bloomberg School of Public Health [Baltimore]
2 St George's, University of London
3 Zambart Health Economics Unit Lusaka
4 University Teaching Hospital (UTH), Lusaka,
5 UTH - University Teaching Hospital [Lusaka]
6 Institute for Medical Research and Training, University of Teaching Lusaka
7 Department of Internal Medicine and Directorate of Research and Post-graduate Studies, Lusaka Apex Medical University, Zambia
8 University of Malawi
9 UCL - University College of London [London]
10 UNC Project - University of North Carolina Project-Malawi
11 UNC - University of North Carolina [Chapel Hill]
12 Hôpital Central de Yaoundé [Yaoundé]
13 Université de Dschang
14 Hôpital Général de Douala
15 Mycologie moléculaire - Molecular Mycology
16 CNRMA - Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire
17 NIMR - National Institute for Medical Research - Muhimbili Research Centre
18 Zomba Central Hospital Malawi
19 University of Toronto
20 LSHTM - London School of Hygiene and Tropical Medicine
21 Bostwana Harvard AIDS Institute Partneship Gaborone
22 Centre d'infectiologie Necker-Pasteur [CHU Necker]
23 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
24 Johns Hopkins Bloomberg School of Public Health [Baltimore]
Thomas Harrison
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1014725
Connectez-vous pour contacter l'auteur
Résumé
BACKGROUND:
Mortality from cryptococcal meningitis remains very high in Africa. In the ACTA trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly than 2-week amphotericin-based regimens. However, many African settings treat with FLU monotherapy and the cost effectiveness of adding 5FC to FLU is uncertain.
METHODS:
Effectiveness and costs of FLU+5FC were taken from ACTA, which included costing analysis at the Zambian site. Effectiveness of FLU was derived from cohorts of consecutively enrolled patients, managed in respects other than drug therapy, as were participants in ACTA. FLU costs were derived from costs of FLU+5FC in ACTA, by subtraction of 5FC drug and monitoring costs.Cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis assessed uncertainties, and a bivariate deterministic sensitivity analysis examined the impact of varying mortality and 5FC drug costs on the ICER.
RESULTS:
Mean costs per patient were US$847 (95%CI:776-927) for FLU+5FC, and US$628 (95%CI:557-709) for FLU. 10 week mortality was 35.1% (95%CI 28.9-41.7) with FLU+5FC and 53.8% (95%CI: 43.1-64.1) with FLU. At the current 5FC price of $US1.30 per 500mg tablet, the ICER of 5FC+FLU versus FLU alone was US$65 (95%CI: 28-208) per life year saved. Reducing 5FC cost to between US$0.80 and US$0.40 per 500mg resulted in an ICER between US$44 and US$28 per life year saved.
CONCLUSIONS:
Addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in Africa and if made available widely could substantially reduce mortality rates among HIV-infected persons in Africa.
Domaines
MycologieFormat du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Résumé |
en
BACKGROUND:
Mortality from cryptococcal meningitis remains very high in Africa. In the ACTA trial, 2 weeks of fluconazole (FLU) plus flucytosine (5FC) was as effective and less costly than 2-week amphotericin-based regimens. However, many African settings treat with FLU monotherapy and the cost effectiveness of adding 5FC to FLU is uncertain.
METHODS:
Effectiveness and costs of FLU+5FC were taken from ACTA, which included costing analysis at the Zambian site. Effectiveness of FLU was derived from cohorts of consecutively enrolled patients, managed in respects other than drug therapy, as were participants in ACTA. FLU costs were derived from costs of FLU+5FC in ACTA, by subtraction of 5FC drug and monitoring costs.Cost-effectiveness of FLU+5FC vs FLU alone was measured as the incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis assessed uncertainties, and a bivariate deterministic sensitivity analysis examined the impact of varying mortality and 5FC drug costs on the ICER.
RESULTS:
Mean costs per patient were US$847 (95%CI:776-927) for FLU+5FC, and US$628 (95%CI:557-709) for FLU. 10 week mortality was 35.1% (95%CI 28.9-41.7) with FLU+5FC and 53.8% (95%CI: 43.1-64.1) with FLU. At the current 5FC price of $US1.30 per 500mg tablet, the ICER of 5FC+FLU versus FLU alone was US$65 (95%CI: 28-208) per life year saved. Reducing 5FC cost to between US$0.80 and US$0.40 per 500mg resulted in an ICER between US$44 and US$28 per life year saved.
CONCLUSIONS:
Addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in Africa and if made available widely could substantially reduce mortality rates among HIV-infected persons in Africa.
|
Titre |
en
Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
|
Auteur(s) |
Tinevimbo Shiri
1
, Angela Loyse
2
, Lawrence Mwenge
3
, Tao Chen
1
, Shabir Lakhi
4
, Duncan Chanda
5, 6
, Peter Mwaba
7
, Síle Molloy
2
, Robert S Heyderman
8, 9
, Cecilia Kanyama
10
, Mina Hosseinipour
10, 11
, Charles Kouanfack
12, 13
, Elvis Temfack
14, 15, 16
, Sayoki G Mfinanga
17, 1
, Sokoine Kivuyo
17
, Adrienne Chan
18, 19
, Joseph Jarvis
20, 21
, Olivier Lortholary
22, 15, 16, 23
, Shabbar Jaffar
1
, Louis Niessen
1, 24
, Thomas Harrison
2
1
LSTM -
Liverpool School of Tropical Medicine
( 166420 )
- Pembroke Place, Liverpool L3 5QA, UK
- Royaume-Uni
2
St George's, University of London
( 327823 )
- Cranmer Terrace, London SW17 0RE, Royaume-Uni
- Royaume-Uni
3
Zambart Health Economics Unit Lusaka
( 565442 )
- Zambie
4
University Teaching Hospital (UTH), Lusaka,
( 553443 )
- Zambie
5
UTH -
University Teaching Hospital [Lusaka]
( 563772 )
- Zambie
6
Institute for Medical Research and Training, University of Teaching Lusaka
( 565443 )
- Zambie
7
Department of Internal Medicine and Directorate of Research and Post-graduate Studies, Lusaka Apex Medical University, Zambia
( 565444 )
- Zambie
8
University of Malawi
( 331417 )
- Malawi
9
UCL -
University College of London [London]
( 300875 )
- Gower Street, London WC1E 6BT
- Royaume-Uni
10
UNC Project -
University of North Carolina Project-Malawi
( 519314 )
- Kamuzu Central Hospital in Malawi's capital, Lilongwe.
- Malawi
11
UNC -
University of North Carolina [Chapel Hill]
( 44261 )
- 250 East Franklin Street, Chapel Hill, NC,
- États-Unis
12
Hôpital Central de Yaoundé [Yaoundé]
( 343185 )
- Briqueterie, Yaoundé
- Cameroun
13
Université de Dschang
( 366272 )
- B.P. 96 Dschang, Cameroun Colline de Foto
- Cameroun
14
Hôpital Général de Douala
( 343186 )
- Cameroun
15
Mycologie moléculaire - Molecular Mycology
( 540289 )
- Département de mycologie
25-28, rue du Docteur Roux
75724 Paris cedex 15
- France
16
CNRMA -
Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire
( 205202 )
- Département de Mycologie - 25-28 rue du Docteur Roux 75724 Paris Cedex 15
- France
17
NIMR -
National Institute for Medical Research - Muhimbili Research Centre
( 98572 )
- Dar Es Salaam
- Tanzanie
18
Zomba Central Hospital Malawi
( 565447 )
- Malawi
19
University of Toronto
( 300722 )
- 27 King's College Circle, Toronto M5S 1A1
- Canada
20
LSHTM -
London School of Hygiene and Tropical Medicine
( 353798 )
- Keppel Street
London
WC1E 7HT
- Royaume-Uni
21
Bostwana Harvard AIDS Institute Partneship Gaborone
( 565448 )
- Botswana
22
Centre d'infectiologie Necker-Pasteur [CHU Necker]
( 181780 )
- Service des Maladies infectieuses et Tropicales
Bâtiment Jean Hamburger
149 rue de Sèvres
75015 Paris
- France
23
Imagine - U1163 -
Imagine - Institut des maladies génétiques (IHU)
( 1004662 )
- IHU Imagine,
156 rue de Vaugirard, 75015 PARIS
et
24 Boulevard du Montparnasse, 75015 Paris
- France
24
Johns Hopkins Bloomberg School of Public Health [Baltimore]
( 466567 )
- 615 N Wolfe St, Baltimore, MD 21205
- États-Unis
|
Langue du document |
Anglais
|
Nom de la revue |
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication |
2019-02-28
|
Volume |
2019
|
Page/Identifiant |
ciz163
|
Licence |
Paternité
|
Collaboration/Projet |
|
Financement |
|
Domaine(s) |
|
Mots-clés |
en
cryptococcal meningitis, treatment, flucytosine, fluconazole, cost-effectiveness
|
DOI | 10.1093/cid/ciz163 |
Pubmed Id | 30816418 |
Loading...